<DOC>
	<DOC>NCT00527267</DOC>
	<brief_summary>Subjects on Hemodialysis will be randomized to AMG 073 or placebo. The screening period is a maximum of 30 days followed by a 26-week treatment period. Lab assessments will be completed throughout the study along with PRO assessments.</brief_summary>
	<brief_title>Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Men and Women greater than or equal to 18 years of age Using effective contraceptive measures Mean iPTH during screening of greater than or equal to 300 pg/mL Mean calcium during screening of greater than or equal to 8.4 mg/dL Stable on hemodialysis Unstable medical conditions Parathyroidectomy within 3 months Change in Vitamin D therapy Receiving antidepressants Experienced an MI within 3 months Inability to swallow tablets Previously received AMG 073</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>